Nasus Pharma Ltd.

https://www.nasuspharma.com

Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company based in Tel Aviv, Israel, focused on developing powder-based intranasal products to address acute medical conditions and public health threats. The company's mission is to provide enhanced protection to patients during severe, life-threatening situations through effective, user-friendly, safe, and rapidly acting intranasal therapies.

Leveraging its proprietary Powder-Based Intranasal (PBI) or Nasax® technology, Nasus Pharma's pipeline includes NS002, an intranasal epinephrine product candidate for anaphylaxis, which is its lead program. The company also developed NS001, an intranasal naloxone powder nasal spray for opioid overdose, though work on this product has been paused and it is available for partnering. Additionally, Nasus Pharma is advancing early-stage programs such as NS003 for nausea and vomiting, NS004 for metabolic disorders, and NS005 for cardiovascular diseases.

Recent developments include positive Phase 2 data for NS002, demonstrating significantly faster and superior epinephrine delivery compared to EpiPen®, with a pivotal study planned for Q4 2026. In February 2026, the company completed a $15.0 million private placement to support the advancement of NS002 and its pipeline. Nasus Pharma became publicly traded in August 2025 following an IPO that raised $10 million. The leadership team includes CEO Dan Teleman, Co-founder and Chief Development Officer Dr. Dalia Megiddo, and Executive Vice President and CFO Eyal Rubin.

Latest updates

Nasus Pharma Advances Epinephrine Candidate, Bolsters Pipeline with Early-Stage Programs

Event summary

  • Nasus Pharma reported positive topline results from Phase 2 trials for NS002, its intranasal epinephrine candidate, demonstrating statistically significant improvements in absorption compared to EpiPen®.
  • The company plans to initiate a pivotal clinical study for NS002 in Q4 2026, with a potential readout in Q1 2027.
  • Nasus Pharma’s cash position stands at $4.3 million as of December 31, 2025, sufficient to fund operations through Q2 2027 following a $15 million private placement in February 2026.
  • The company is advancing NS003 (Ondansetron), NS004 (metabolic), and NS005 (cardiovascular) into preclinical development, with Phase 1 studies expected in H2 2026.

The big picture

Nasus Pharma’s progress with NS002 represents a potential disruption to the anaphylaxis treatment market, which is dominated by autoinjectors. The company's focus on intranasal delivery offers a needle-free alternative, addressing a key patient and caregiver need. However, the company's success hinges on navigating regulatory hurdles and demonstrating a clear clinical advantage over existing therapies, while also expanding its pipeline beyond NS002.

What we're watching

Clinical Execution
The success of the planned pivotal study for NS002 will be critical; any delays or adverse findings could significantly impact the company's valuation.
Pipeline Diversification
The progress of NS003, NS004, and NS005 into Phase 1 trials will reveal the viability of Nasus Pharma’s broader intranasal platform and its ability to expand beyond epinephrine.
Competitive Landscape
Nasus Pharma's ability to differentiate NS002 and secure market share against established epinephrine autoinjectors, like EpiPen®, will depend on demonstrating superior efficacy and ease of use.

Nasus Pharma Phase 2 Data Shows Faster Epinephrine Delivery vs. EpiPen

Event summary

  • Nasus Pharma's Phase 2 clinical study demonstrated NS002 achieved a median T100 of 1.69 minutes versus EpiPen’s 3.42 minutes (p=0.033).
  • At 5 minutes, 88.4% of NS002 subjects reached the therapeutic threshold compared to 64.6% with EpiPen® (p=0.0081).
  • The company plans to initiate a pivotal clinical study in Q4 2026.
  • The study enrolled 50 healthy adults with a history of allergic rhinitis.

The big picture

Nasus Pharma's NS002 represents a potential disruption to the anaphylaxis treatment market, currently dominated by Mylan’s EpiPen. The faster delivery demonstrated in Phase 2 data could offer a significant clinical benefit for patients experiencing anaphylaxis, but the company faces the challenge of displacing a widely used and familiar product. The success of NS002 hinges on demonstrating sustained advantages in larger trials and navigating the complexities of pharmaceutical market adoption.

What we're watching

Regulatory Approval
The success of the pivotal trial and subsequent regulatory review will be critical, as any delays could significantly impact Nasus Pharma’s timeline for market entry.
Market Adoption
The company's ability to effectively market NS002 and displace EpiPen, a well-established product, will depend on demonstrating clear clinical advantages and securing favorable reimbursement.
Manufacturing Scale
Nasus Pharma will need to rapidly scale up manufacturing of its Nasax® powder platform to meet potential demand following commercial launch, which could present logistical and financial challenges.

Nasus Pharma to Detail Phase 2 Epinephrine Data Next Week

Event summary

  • Nasus Pharma will present topline data from a Phase 2 repeated dose clinical study of NS002, its intranasal epinephrine product candidate, on March 16, 2026.
  • The conference call and webcast will begin at 8:00 a.m. ET.
  • NS002 is being developed as a needle-free alternative to epinephrine autoinjectors for anaphylaxis.
  • The company utilizes a proprietary powder-based intranasal (“PBI”) technology for rapid drug delivery.

The big picture

Nasus Pharma's NS002 represents a potential disruption to the anaphylaxis treatment market, which is dominated by epinephrine autoinjectors. The Phase 2 data will be a key indicator of the viability of intranasal delivery as a superior alternative, potentially attracting significant investor interest. Success hinges on demonstrating both clinical efficacy and a clear path to regulatory approval and market access.

What we're watching

Clinical Efficacy
The topline data will reveal whether NS002 demonstrates sufficient efficacy compared to existing epinephrine delivery methods, a critical factor for potential market adoption.
Regulatory Pathway
The FDA's potential acceptance of intranasal epinephrine as a viable alternative to autoinjectors will significantly influence Nasus Pharma’s development timeline and commercial prospects.
Commercialization
The ease of use and needle-free nature of NS002 could drive rapid adoption if clinical results are positive, but manufacturing scalability and reimbursement hurdles remain significant challenges.

Nasus Pharma to Detail Pipeline at Investor Forum

Event summary

  • Nasus Pharma will present at the virtual Life Sciences Investor Forum on March 11, 2026, at 12:30 p.m. ET.
  • CEO Dan Teleman will lead the presentation, with one-on-one meetings available by request.
  • The forum is hosted by VirtualInvestorConferences.com and registration is available via a provided link.
  • Nasus Pharma is developing NS002, an intranasal epinephrine product candidate as a needle-free alternative for anaphylaxis.

The big picture

Nasus Pharma’s focus on intranasal drug delivery addresses a growing need for rapid and convenient administration of emergency medications. The company’s PBI technology represents a potential advantage over existing liquid nasal formulations, but faces competition from established autoinjector manufacturers. Investor interest will hinge on demonstrating clinical efficacy and a viable path to commercialization within a crowded market.

What we're watching

Clinical Progress
The forum presentation will likely highlight progress on NS002, and the success of the trial will be critical to investor confidence given the competitive landscape of epinephrine delivery methods.
Market Adoption
The ease of use and needle-free nature of Nasus’ intranasal delivery system could drive adoption, but the company must demonstrate a clear value proposition and overcome potential patient and physician hesitancy.
Financial Runway
Given the clinical-stage nature of Nasus Pharma, the company’s ability to secure additional funding or partnerships will be essential to support ongoing development and commercialization efforts.

Nasus Pharma to Aggressively Court Investors Across Three Conferences

Event summary

  • Nasus Pharma is scheduled to present at three investor conferences in February and March 2026.
  • CEO Dan Teleman will represent the company at all three events: Oppenheimer Healthcare Life Sciences Conference (Feb 25), BIO Investment & Growth Summit (Mar 2), and Citizens Life Sciences Conference (Mar 11).
  • The conferences will include both virtual and in-person components, with the Miami events taking place in Florida.
  • Management will be available for one-on-one meetings with interested parties.

The big picture

Nasus Pharma’s aggressive conference schedule signals a heightened focus on investor relations as the company progresses its clinical pipeline. The company’s reliance on a novel intranasal delivery method for epinephrine, a market dominated by established players, necessitates consistent and persuasive communication to secure funding and market acceptance. This proactive approach to investor engagement is common for clinical-stage biopharma companies seeking to raise capital and build awareness.

What we're watching

Capital Allocation
The frequency and intensity of investor presentations suggest Nasus Pharma is actively seeking to bolster its investor base, potentially to fund ongoing clinical trials or future expansion.
Clinical Progress
The content of the presentations will likely focus on the progress of NS002, and investor sentiment will hinge on any updates regarding clinical trial timelines and results.
Market Positioning
Nasus Pharma's success will depend on its ability to effectively communicate the advantages of its PBI technology and differentiate its intranasal epinephrine product from existing autoinjectors, and investor reception will reflect this.

Nasus Pharma Data Suggests Potential Edge in Epinephrine Delivery

Event summary

  • Nasus Pharma will present data at AAAAI 2026 on NS002, its intranasal epinephrine powder formulation.
  • Data suggests NS002 demonstrates superior nasal deposition and stability compared to liquid nasal sprays.
  • Two poster presentations (IDs 592 and 593) will be given on March 1, 2026, at 9:45 AM.
  • The company claims NS002 offers a potentially faster and needle-free alternative for anaphylaxis treatment.

The big picture

The anaphylaxis treatment market is dominated by epinephrine autoinjectors, and Nasus Pharma's NS002 represents a potential disruption with its needle-free, intranasal delivery. The company’s PBI technology aims to address limitations of current treatments, particularly the need for rapid drug delivery in emergency situations. Success hinges on demonstrating a clear clinical benefit and navigating regulatory hurdles for a novel drug delivery system.

What we're watching

Clinical Validation
The data presented at AAAAI 2026 will be crucial in validating Nasus Pharma’s claims of superior absorption and stability, and the market will scrutinize the methodology and results for potential biases.
Regulatory Pathway
How the FDA views the novel delivery method and the comparative data against existing epinephrine autoinjectors will significantly influence the timeline and cost of regulatory approval for NS002.
Market Adoption
The success of NS002 will depend on physician and patient acceptance of a powder-based intranasal epinephrine product, and Nasus Pharma must demonstrate clear advantages over existing needle-based solutions to drive adoption.

Nasus Pharma Lands $15M Private Placement to Advance Epinephrine Candidate

Event summary

  • Nasus Pharma closed a private placement of ordinary shares and warrants, raising gross proceeds of approximately $15.0 million.
  • The placement included 2,695,425 ordinary shares and accompanying warrants, priced at $5.565 per share/warrant.
  • Citizens Capital Markets acted as lead placement agent, with Laidlaw & Company (UK) Ltd. as co-placement agent.
  • Proceeds will primarily fund the pivotal clinical development of NS002, Nasus Pharma’s intranasal epinephrine product, and initial studies for other pipeline products.

The big picture

This private placement provides Nasus Pharma with a crucial runway to advance its lead candidate, NS002, through a pivotal trial and towards potential regulatory approval. The company's focus on intranasal drug delivery represents a niche approach within the broader pharmaceutical sector, aiming to improve drug delivery and patient outcomes. The participation of institutional investors suggests a degree of confidence in Nasus Pharma’s technology and market opportunity, but the company will need to demonstrate clinical efficacy and commercial viability to justify this valuation.

What we're watching

Clinical Execution
The success of the NS002 pivotal study will be critical; a failure could significantly impact investor confidence and future funding prospects.
Warrant Dynamics
The warrants’ expiration tied to NS002 trial results create a potential overhang; a positive outcome could trigger exercise and dilute existing shareholders.
Pipeline Expansion
Nasus Pharma’s ability to successfully advance other intranasal programs beyond NS002 will determine the long-term viability of its platform technology.

Nasus Pharma's Epinephrine Candidate Shows Faster Absorption in Phase 2

Event summary

  • Nasus Pharma announced positive interim results from a Phase 2 clinical study of NS002, an intranasal epinephrine powder.
  • The study demonstrated NS002 achieved faster absorption (Tmax of 10.8 minutes vs. 15 minutes for EpiPen®) and higher peak epinephrine levels (655 pg/ml vs. 548 pg/ml).
  • 91% of participants reached a 100 pg/ml plasma threshold at 5 minutes with NS002, compared to 67% with EpiPen®.
  • Full Phase 2 results are expected by the end of Q1 2026, with a pivotal study planned for Q4 2026.

The big picture

The anaphylaxis treatment market is dominated by epinephrine autoinjectors, but faces challenges with patient compliance and delayed administration. Nasus Pharma's NS002, with its faster absorption and needle-free delivery, represents a potential disruption, but faces the challenge of demonstrating a significant clinical advantage and securing regulatory approval. The company's ability to successfully navigate the pivotal trial and commercial launch will be key to unlocking the value of its Nasax® platform.

What we're watching

Regulatory Pathway
The FDA's acceptance of Nasus Pharma's non-clinical data package and potential for accelerated approval pathways will be critical given the unmet need for faster-acting epinephrine delivery.
Commercial Adoption
The success of NS002 will hinge on physician and patient adoption, which will depend on demonstrating a clear clinical benefit over EpiPen® and overcoming potential reimbursement hurdles.
Platform Risk
Nasus Pharma's reliance on its Nasax® platform technology for future product development introduces execution risk, as the success of NS002 may not guarantee success for other intranasal formulations.

Nasus Pharma Advances Epinephrine Delivery, Secures Funding and Regulatory Nod

Event summary

  • Nasus Pharma, a clinical-stage pharmaceutical company, presented positive early clinical trial data for NS002, an intranasal epinephrine powder formulation.
  • The company completed an initial public offering (IPO) in August 2025, raising $10 million in gross proceeds.
  • Nasus Pharma expanded collaboration agreements with Aptar France S.A.S. and AptarGroup Inc. to support NS002’s development and commercialization.
  • Health Canada authorized Nasus Pharma to initiate a Phase 2 clinical study of NS002, with the first patient dosed in October 2025.
  • The company outlined key milestones for 2026, including a Phase 2 readout, IND submission, and initiation of pivotal and pediatric studies.

The big picture

Nasus Pharma's strategy to disrupt epinephrine delivery with a needle-free intranasal formulation addresses a significant unmet need in emergency medicine, where rapid administration is crucial. The successful IPO and collaborations with Aptar demonstrate investor confidence and access to established commercialization infrastructure. However, the company's valuation is heavily reliant on the success of NS002, and competition from established autoinjector manufacturers remains a substantial challenge.

What we're watching

Clinical Outcomes
The interim analysis of the Phase 2 trial, expected in Q1 2026, will be critical in assessing NS002’s pharmacokinetic profile and hemodynamic responses relative to EpiPen®, potentially influencing the trajectory of future development.
Regulatory Pathway
The success of the planned IND submission in Q3 2026 will hinge on the Phase 2 data and the FDA’s assessment of Nasus’s novel intranasal delivery approach, which could face precedent-setting regulatory hurdles.
Pipeline Expansion
The company’s stated goal of initiating first-in-human studies for additional pipeline products in 2026 will test Nasus’s ability to leverage its Nasax technology beyond NS002 and diversify its revenue streams.
CID: 558